Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/ARF6_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/ARF6_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ARF6_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ARF6_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ARF6_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/ARF6_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ARF6_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ARF6_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ARF6_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ARF6_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ARF6_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003086613 | Prostate | Tumor | cortical actin cytoskeleton organization | 15/3246 | 40/18723 | 1.91e-03 | 1.11e-02 | 15 |
GO:003152914 | Prostate | Tumor | ruffle organization | 19/3246 | 56/18723 | 2.02e-03 | 1.16e-02 | 19 |
GO:00515461 | Prostate | Tumor | keratinocyte migration | 9/3246 | 19/18723 | 2.42e-03 | 1.36e-02 | 9 |
GO:004825914 | Prostate | Tumor | regulation of receptor-mediated endocytosis | 31/3246 | 110/18723 | 3.15e-03 | 1.65e-02 | 31 |
GO:190353211 | Prostate | Tumor | positive regulation of secretion by cell | 67/3246 | 282/18723 | 3.53e-03 | 1.82e-02 | 67 |
GO:003134512 | Prostate | Tumor | negative regulation of cell projection organization | 47/3246 | 186/18723 | 3.91e-03 | 1.99e-02 | 47 |
GO:003601011 | Prostate | Tumor | protein localization to endosome | 10/3246 | 24/18723 | 4.46e-03 | 2.20e-02 | 10 |
GO:0051547 | Prostate | Tumor | regulation of keratinocyte migration | 7/3246 | 14/18723 | 5.15e-03 | 2.48e-02 | 7 |
GO:001097711 | Prostate | Tumor | negative regulation of neuron projection development | 36/3246 | 137/18723 | 5.51e-03 | 2.61e-02 | 36 |
GO:00510476 | Prostate | Tumor | positive regulation of secretion | 71/3246 | 310/18723 | 6.95e-03 | 3.13e-02 | 71 |
GO:0051549 | Prostate | Tumor | positive regulation of keratinocyte migration | 6/3246 | 12/18723 | 9.63e-03 | 4.10e-02 | 6 |
GO:005080711 | Prostate | Tumor | regulation of synapse organization | 50/3246 | 211/18723 | 1.11e-02 | 4.56e-02 | 50 |
GO:004873226 | Skin | AK | gland development | 93/1910 | 436/18723 | 3.24e-12 | 7.10e-10 | 93 |
GO:015011520 | Skin | AK | cell-substrate junction organization | 34/1910 | 101/18723 | 1.38e-10 | 2.05e-08 | 34 |
GO:003432919 | Skin | AK | cell junction assembly | 86/1910 | 420/18723 | 1.95e-10 | 2.68e-08 | 86 |
GO:190382927 | Skin | AK | positive regulation of cellular protein localization | 64/1910 | 276/18723 | 2.23e-10 | 3.00e-08 | 64 |
GO:000716326 | Skin | AK | establishment or maintenance of cell polarity | 53/1910 | 218/18723 | 1.32e-09 | 1.26e-07 | 53 |
GO:015011620 | Skin | AK | regulation of cell-substrate junction organization | 26/1910 | 71/18723 | 2.60e-09 | 2.33e-07 | 26 |
GO:000701528 | Skin | AK | actin filament organization | 85/1910 | 442/18723 | 5.94e-09 | 4.14e-07 | 85 |
GO:190290328 | Skin | AK | regulation of supramolecular fiber organization | 75/1910 | 383/18723 | 2.11e-08 | 1.20e-06 | 75 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ARF6 | SNV | Missense_Mutation | novel | c.390N>C | p.Met130Ile | p.M130I | P62330 | protein_coding | deleterious_low_confidence(0.03) | benign(0.029) | TCGA-C5-A2LY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
ARF6 | SNV | Missense_Mutation | | c.433N>T | p.Arg145Trp | p.R145W | P62330 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.848) | TCGA-EK-A2RA-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
ARF6 | SNV | Missense_Mutation | | c.91N>C | p.Tyr31His | p.Y31H | P62330 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(1) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
ARF6 | SNV | Missense_Mutation | | c.433C>T | p.Arg145Trp | p.R145W | P62330 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.848) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ARF6 | SNV | Missense_Mutation | | c.415N>A | p.Leu139Met | p.L139M | P62330 | protein_coding | deleterious_low_confidence(0.04) | benign(0.41) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ARF6 | SNV | Missense_Mutation | | c.418N>T | p.Gly140Cys | p.G140C | P62330 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.884) | TCGA-AP-A0LD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ARF6 | SNV | Missense_Mutation | | c.448N>C | p.Tyr150His | p.Y150H | P62330 | protein_coding | tolerated_low_confidence(0.15) | possibly_damaging(0.503) | TCGA-BS-A0UJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ARF6 | SNV | Missense_Mutation | novel | c.246N>C | p.Gln82His | p.Q82H | P62330 | protein_coding | tolerated_low_confidence(0.05) | probably_damaging(0.968) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ARF6 | SNV | Missense_Mutation | novel | c.446G>T | p.Trp149Leu | p.W149L | P62330 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.968) | TCGA-EO-A3KX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ARF6 | SNV | Missense_Mutation | novel | c.102N>T | p.Lys34Asn | p.K34N | P62330 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.989) | TCGA-91-8499-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |